BRAF突变型非小细胞肺癌免疫检查点抑制剂治疗进展

Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer

在非小细胞肺癌(non-small cell lung cancer, NSCLC)患者中,约2%-4%有BRAF基因突变,该型肿瘤恶性程度高、化疗有效率低、预后差。尽管BRAF抑制剂及MEK抑制剂联合治疗在BRAF V600E突变的晚期NSCLC患者中成效显著,已被写入美国国家综合癌症网络(National Comprehensive Cancer Network, NCCN)指南,但两药联合副作用发生率高,耐药之后尚无有效治疗策略,且针对非V600E突变患者仍缺乏靶向治疗方案。本文将针对BRAF突变型NSCLC免疫标志物表达情况以及免疫检查点抑制剂(immune checkpoint inhibitor, ICI)疗效相关研究做一综述,为延长患者生存提供更多选择方案。

BRAF gene mutation is found in about 2%-4%of the patients with non-small cell lung cancer(NSCLC).This type of NSCLC is characterized by high malignancy,low efficacy of chemotherapy and poor prognosis.Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable results in advanced NSCLC patients with BRAF V600E mutation,which has been written into the National Comprehensive Cancer Network(NCCN)guidelines,severe side effects of the combination therapy are frequently observed.There isn’t effective treatment strategy after drug resistance,and targeted therapy for non-V600E mutation patients is still lacking.In this paper,we summarized the researches on expression of immune markers in NSCLC patients with mutant BRAF and analyzed the studies on efficacy of immune checkpoint inhibitor(ICI),so as to provide more options for prolonging survival of the patients.